These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33657663)

  • 21. Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
    Lim EL; Cugliandolo FM; Rosner DR; Gyori D; Roychoudhuri R; Okkenhaug K
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Idelalisib.
    Zirlik K; Veelken H
    Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.
    Compagno M; Wang Q; Pighi C; Cheong TC; Meng FL; Poggio T; Yeap LS; Karaca E; Blasco RB; Langellotto F; Ambrogio C; Voena C; Wiestner A; Kasar SN; Brown JR; Sun J; Wu CJ; Gostissa M; Alt FW; Chiarle R
    Nature; 2017 Feb; 542(7642):489-493. PubMed ID: 28199309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A highly selective PI3Kδ inhibitor BGB-10188 shows superior preclinical anti-tumor activities and decreased on-target side effects on colon.
    Yang X; Bai H; Yuan X; Yang X; Liu Y; Guo M; Hu N; Jiang B; Lian Z; Ma Z; Wang J; Sun X; Zhang T; Su D; Wu Y; Li J; Wang F; Wang Z; Wang L; Liu X; Song X
    Neoplasia; 2024 Nov; 57():101053. PubMed ID: 39260132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas.
    Lou SY; Zheng FL; Tang YM; Zheng YN; Lu J; An H; Zhang EJ; Cui SL; Zhao HJ
    Life Sci; 2024 Jun; 347():122662. PubMed ID: 38670450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular modeling strategy for detailing the primary mechanism of action of copanlisib to PI3K: combined ligand-based and target-based approach.
    Zhu J; Li X; Meng H; Jia L; Xu L; Cai Y; Chen Y; Jin J; Yu L; Gao M
    J Biomol Struct Dyn; 2024 Sep; 42(15):8172-8183. PubMed ID: 37572326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of New Phosphoinositide 3-kinase Delta (PI3Kδ) Inhibitors via Virtual Screening using Crystallography-derived Pharmacophore Modelling and QSAR Analysis.
    Al-Sha'er MA; Al-Aqtash RA; Taha MO
    Med Chem; 2019; 15(6):588-601. PubMed ID: 30799792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
    Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
    Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
    Chellappa S; Kushekhar K; Munthe LA; Tjønnfjord GE; Aandahl EM; Okkenhaug K; Taskén K
    J Immunol; 2019 Mar; 202(5):1397-1405. PubMed ID: 30692213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
    Shah A; Mangaonkar A
    Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of WO2014075392 and WO2014075393, Merck's first PI3Kδ inhibitor filings.
    Norman P
    Expert Opin Ther Pat; 2014 Nov; 24(11):1277-82. PubMed ID: 25326077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):651-656. PubMed ID: 29536777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
    Zhu J; Pan P; Li Y; Wang M; Li D; Cao B; Mao X; Hou T
    Mol Biosyst; 2014 Mar; 10(3):454-66. PubMed ID: 24336903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
    Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
    Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential.
    Barrachina MN; Izquierdo I; Hermida-Nogueira L; Morán LA; Pérez A; Arroyo AB; García-Barberá N; González-Conejero R; Troitiño S; Eble JA; Rivera J; Martínez C; Loza MI; Domínguez E; García Á
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33804911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of novel quinazoline derivatives as potent PI3Kδ inhibitors with high selectivity.
    Teng Y; Li X; Ren S; Cheng Y; Xi K; Shen H; Ma W; Luo G; Xiang H
    Eur J Med Chem; 2020 Dec; 208():112865. PubMed ID: 32987316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-ones based novel, potent and PI3Kδ selective inhibitors.
    Bahekar R; Dave B; Soman S; Patel D; Chopade R; Funde R; Kumar J; Sachchidanand S; Giri P; Chatterjee A; Mahapatra J; Vyas P; Ghoshdastidar K; Bandyopadhyay D; Desai RC
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1313-1319. PubMed ID: 30975623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
    Lampson BL; Brown JR
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitory Effect of Idelalisib, a Selective Phosphatidylinositol 3-Kinase δ Inhibitor, on Adipogenesis in an In Vitro Model of Graves' Orbitopathy.
    Ko J; Kim JY; Lee EJ; Yoon JS
    Invest Ophthalmol Vis Sci; 2018 Sep; 59(11):4477-4485. PubMed ID: 30193323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Idelalisib induces apoptosis in the lymphoid tissues and impairs lung function in mice.
    George JA; Alshebli Z; Alneyadi A; Al Mukhaini N; Al-Salam S; Sudhadevi M; Souid AK; Alsuwaidi AR
    J Chemother; 2020 Apr; 32(2):88-97. PubMed ID: 31884896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.